A comparison of reboxetine and amitryptilline in the treatment of fibromyalgia syndrome with co-morbid depressive symptoms: An open-label preliminary study

Klinik Psikofarmakoloji Bulteni

Volumn 20, Issue 1, 2010, Pages 29-37

  Konuk, Numan ^a   Ortancil, Ozgur ^b   Bostanci, Bora ^b   Kiran, Sibel ^b   Sapmaz, Perihan ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Zonguldak Karaelmas University   (Turkey)

Author keywords

Amitryptilline; Antidepressants; Fibromyalgia; Reboxetine

Indexed keywords

AMITRIPTYLINE; NORADRENALIN; REBOXETINE;

ADULT; AGED; ANXIETY; ARTICLE; BECK ANXIETY INVENTORY; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; HAMILTON SCALE; HUMAN; NEUROTRANSMITTER UPTAKE; OPEN STUDY; PAIN ASSESSMENT; PATIENT COMPLIANCE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT DURATION; VISUAL ANALOG SCALE; XEROSTOMIA;

EID: 77957170293     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: 10.1080/10177833.2010.11790631     Document Type: Article

References (53)

1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-172.
2. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
3. Nicassio PM, Weisman MH, Schuman C, Young CW. The role of generalized pain and pain behavior in tender point scores in fibromyalgia. J Rheumatol. 2000;27:1056-1062. (Pubitemid 30389768)
4. McBeth J, Silman AJ. The role of psychiatric disorders in fibromyalgia. Curr Rheumatol Rep 2001;3:157-164.
5. Ahles TA, Khan SA, Yunus MB, Spiegell DA, Masi AT. Psychiatric status of patients with primary fibromyalgia, patients with rheumatoid arthritis and subjects without pain: a blind comparison of DSM-III diagnoses. Am J Psychiatry 1991;148:1721-1726.
6. Hudson JL, Goldenberg DL, Pope Jr HG, Keck Jr PK, Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 1992 ;92;363-367.
7. Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000;41:104-113.
8. Versiani M, Ontiveros A, Mazzotti G, Ospina J, Dávila J, Mata S, Pacheco A, Plewes J, Tamura R, Palacios M. Fluoxetine versus amitryptiline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison. Int Clin Psychopharmacol. 1999;14:321-327.
9. Kiser RS, Cohen HM, Freedenfeld RN, Jewell C, Fuchs PN. Olanzapine for the Treatment of Fibromyalgia Symptoms. Journal of Pain and Symptom Management 2001; 22; 2: 704-708.
10. Bomholt SF, Mikkelsen JD, Blackburn-Munro G. Antinociceptive effects of the antidepressants amitryptiline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology. 2005;48:252-263. (Pubitemid 40208261)
11. Moret C, Briley M. Antidepressants in the treatment of fibromyalgia. Neuropsychiatr Dis Treat. 2006;2:537-548.
12. Ardid D, Guilbaud G. Antinociceptive effects of acute and 'chronic' injections of tricyclic antidepressant drugs in a new model of mononeuropathy in rats. Pain. 1992;49:279-287.
13. Esser MJ, Sawynok J. Acute amitryptylline in a rat model of neuropathic pain: differential symptom and route effects. Pain. 1999;80:643-653. (Pubitemid 29182714)
14. Sawynok J, Esser MJ, Reid AR. Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat. Pain. 1999;82:149-158. (Pubitemid 29317527)
15. O'Malley PG, Balden E, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of fibromyalgia with antidepressants: Ameta-analysis. J Gen Intern Med. 2000; 15:659-666.
16. Goldenberg DL, Mayskiy M, Mossey C, Ruthazer R, Schmid CH A randomized, double- blind crossover trial of fluoxetine and amitryptiline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39:1852-1859.
17. Nørregaard J, Volkmann H, Danneskiold-Samsø B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain. 1995;61:445-449.
18. Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother. 2003;37:1561-1565.
19. Hannonen P, Malminiemi K, Yli-Kerttula U, Isomeri R, Roponen P. A randomized, double-blind, placebo-controlled study of moclobemide and amitryptiline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol. 1998;37:1279-1286.
20. Akkaya C, Sivrioglu EY, Akgoz S, Eker SS, Kirli S. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study. Hum Psychopharmacol. 2006;21:337-345. (Pubitemid 44203217)
21. Krell HV, Leuchter AF, Cook IA, Abrams M. Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain. Psychosomatics. 2005;46:379-384. (Pubitemid 46173196)
22. Aragona M, Bancheri L, Perinelli D, Tarsitani L, Pizzimenti A, Conte A, Inghilleri M. Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder. Eur J Pain. 2005;9:33-38. (Pubitemid 40075397)
23. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for the DSM-IV Axis I Disorders - patient edition (SCID -I/P,version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute, 1995.
24. First MB, Spitzer RL, Gibbon M, Williams JBW: DSM-IV Eksen IBozukluklari Icin Yapilandirilmis Klinik Gorusme. [Translated by A Corapcioglu]. Ankara: Hekimler Yayin Birligi, 1995.
25. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991;18:728-733.
26. Sarmer S, Ergin S, Yavuzer G. The validity and reliability of the Turkish version of the Fibromyalgia Impact Questionnaire. Rheumatol Int 2000;20:9-12.
27. Beck AT, Waed CH, Mendelson M. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
28. Hisli N. The reliability and validity study of the Beck Depression Inventory in a Turkish sample. Turkish. Psikoloji Dergisi 1988;6:118-122. (in Turkish)
29. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893-897. (Pubitemid 19008360)
30. Ulusoy M, Sahin NH, Erkmen H. Turkish version of the Beck Anxiety Inventory: psychometric properties. J Cognitive Psychother 1998;12:163-172.
31. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
32. Hamilton M. The assessment of anxiety disorders by rating. Br J Med Psychol 1959;32:50-65.
33. Yazici MK, Demir B, Tanriverdi N, Karaagaoglu E, Yolac P. [Hamilton anxiety scale, inter-rater reliability and validity study] Turkish. Turk Psikiyatri Dergisi 1998;9:114-117.
34. Akdemir A, Turkcapar MH, Orsel SD, Demirergi N, Dag I, Ozbay MH. Reliability and validity of the Turkish version of the Hamilton Depression Rating Scale. Compr Psychiatry 2001;42:161-165. (Pubitemid 32207252)
35. Hujkisson HC. Visual analog scales. In: Handbook of psychiatric measures. Washington, DC: American Psychiatric Press, 2000:601-603.
36. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs, and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica Suppl 1987;76:1-100.
37. SPSS for Windows, Version 11.01, Chicago, IL , 2001, customer ID number 114094.
38. Thieme K, Turk DC, Flor H. Comorbid depression and anxiety in fibromyalgia syndrome: relationship to somatic and psychosocial variables. Psychosom Med. 2004;66:837-844. (Pubitemid 39552866)
39. Hakimi R. Is fibromyalgia a disease? Regarding the contribution in DMW 23/2004 Dtsch Med Wochenschr 2005; 130:1278-1279.
40. Fishbain D. Evidence-based data on pain relief with antidepressants. Ann Med. 2000;32:305-316. (Pubitemid 30496575)
41. Bergman S. Management of musculoskeletal pain Best Pract Res Clin Rheumatol 2007;21:153-166.
42. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999;83:389-400.
43. Dryson E. Venlafaxine and fibromyalgia. N Z Med J, 2000. 113:87.
44. Dwight MM, Arnold LM, O'Brien H, Metzger R, Morris-Park E, Keck PE Jr. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 1998;39:14-17. (Pubitemid 28152592)
45. Zijlstra TR, Barendregt EJ, van de Laar MA. 2002. Venlafaxine in fibromyalgia: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 46(suppl 9):S105.
46. Sayar K, Aksu G, Ak I, et al. Venlafaxine treatment of fibromyalgia. Ann Pharmacother 2003;37:1561-1565.
47. Nagaoka S, Ohno M, Sekiguchi A. An open-label clinical trial of milnacipran in fibromyalgia syndrome with co-morbid depressive symptoms. Int J Psychiatry Clin Pract 2004; 8:47-51. (Pubitemid 38332459)
48. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15. (Pubitemid 41752960)
49. Leo RJ, Brooks VL. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain. Curr Opin Investig Drugs 2006;7:637-642. (Pubitemid 44018347)
50. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004;311:576-584. (Pubitemid 39391542)
51. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004;19 Suppl 1:S27-S35.
52. Yonkers KA, Brawman-Mintzer O. The pharmacologic treatment of depression: is gender a critical factor? J Clin Psychiatry 2002;63:610-615.
53. Fassbender K, Samborsky W, Kellner M, Müller W, Lautenbacher S. Tender points, depressive and functional symptoms: comparison between fibromyalgia and major depression. Clin Rheumatol 1997;16:76-79. (Pubitemid 27101296)